Poh et al. proved that elevated KLB levels in hepatocellular carcinoma tissues support the elevated FGFR4 signaling in HCC that promotes development, which could serve as a novel biomarker for identifying patients who may benefit from anti-FGFR4 therapy [88]. This evidence concerns the gene KLB and hepatocellular carcinoma.